Zobrazeno 21 - 30
of 88
pro vyhledávání: ''
Autor:
Linda Kessler, Alan L. Ho, Catherine Rose Scholz, Matthew R. Janes, Eric Van Cutsem, Thomas E. Witzig, Vishnu Mishra, Antonio Gualberto
Publikováno v:
Cancer Research. 79:CT191-CT191
Background: CXCL12 is a negative prognostic factor for head & neck (HNSCC) and pancreatic (PDCA) cancers, among others. Its receptor, CXCR4, is a negative prognostic factor in lymphoma/leukemia. CXCR4 signals in part through RAS species, and the expr
Autor:
Niki Karachaliou, Maria de los Llanos Gil, Miguel Angel Molina Vila, Rafael Rosell, Veronika Smutna, Alejandro Martínez Bueno, Valérie Cattan, Nuria Jordana Ariza, Ruth Román Lladó, Lidia Alonso Landeira, Santiago Viteri, Maria Gonzalez Cao, Mónica Garzón Ibañez
Publikováno v:
Cancer Research. 79:2521-2521
Background Non-small cell lung cancer (NSCLC) tumors with mutations in the EGF receptor (EGFR) relapse to therapy with EGFR tyrosine kinase inhibitors (EGFR TKIs) due to a variety of mechanisms, such as emergence resistance mutations, dysregulation o
Autor:
Elizabeth Garrett-Mayer, Julie Gottlieb Fisher, Timothy L. Cannon, Pam K. Mangat, Ricardo H. Alvarez, Samiha Islam, Susan Halabi, Andrew L. Rygiel, Kaitlyn R. Antonelli, Theodore Pollock, Suanna S. Bruinooge, Richard L. Schilsky, Jared Addison Cotta, Pamela A. Crilley, Tareq Al Baghdadi
Publikováno v:
Cancer Research. 79:CT135-CT135
Background: The TAPUR Study is a phase II multi-basket study that evaluates the anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations known to be drug targets. Results in two cohorts of BC
Autor:
Katherine Galvin, Shuntarou Tsuchiya, Jouhara Chouitar, Sei Yoshida, Tomoyasu Ishikawa, Jill Donelan, Elizabeth Carideo, Masanori Okaniwa, Takeo Arita, Akito Nakamura
Publikováno v:
Cancer Research. 73:7043-7055
The mitogen-activated protein kinase (MAPK) pathway is particularly important for the survival and proliferation of melanoma cells. Somatic mutations in BRAF and NRAS are frequently observed in melanoma. Recently, the BRAF inhibitors vemurafenib and
Autor:
Roger S. Lo, Varsha Tembe, Helen Rizos, Richard F. Kefford, John F. Thompson, James S. Wilmott, Richard A. Scolyer, Julie Howle, Raghwa Sharma, Georgina V. Long
Publikováno v:
Molecular Cancer Therapeutics. 11:2704-2708
Targeted therapies are increasingly being used to treat a variety of cancers. Their efficacy depends upon the accurate detection and targeting of a specific mutation or aberration in the tumor. All cancers, such as melanoma, are molecularly heterogen
Autor:
Federica Di Nicolantonio, Francesco Galimi, Paolo Massucco, Andrea Bertotti, Alberto Bardelli, Eugenia R. Zanella, Michela Buscarino, Giorgia Migliardi, Livio Trusolino, Lorenzo Capussotti, Davide Torti, Dario Ribero, Silvia Marsoni, Francesco Sassi, Mauro Risio, Alberto Pisacane, Paolo M. Comoglio, Andrea Muratore
Publikováno v:
Clinical Cancer Research
Clinical Cancer Research; Vol 18
Clinical Cancer Research; Vol 18
Purpose: Gene mutations along the Ras pathway (KRAS, NRAS, BRAF, PIK3CA) occur in approximately 50% of colorectal cancers (CRC) and correlate with poor response to anti–EGF receptor (EGFR) therapies. We assessed the effects of mitogen-activated pro
Autor:
Marc Ladanyi, Mark G. Kris, Maria E. Arcila, Gregory J. Riely, Maureen F. Zakowski, Valerie W. Rusch, M. Catherine Pietanza, Camelia S. Sima, Christopher Lau, Paul K. Paik, Jamie E. Chaft
Publikováno v:
Molecular Cancer Therapeutics. 11:485-491
Phosphoinositide-3-kinase catalytic alpha polypeptide (PIK3CA) encodes the p110α subunit of the mitogenic signaling protein phosphoinositide 3-kinase (PI3K). PIK3CA mutations in the helical binding domain and the catalytic subunit of the protein hav
Autor:
Nadia Russolillo, Salvatore Siena, Enzo Medico, Michela Buscarino, Federica Di Nicolantonio, Davide Torti, Paolo Massucco, Alberto Bardelli, Alberto Pisacane, Luca Molinaro, Francesco Galimi, Andrea Bertotti, Mauro Risio, Davide Corà, Emanuele Valtorta, Giorgia Migliardi, Francesco Sassi, Claudio Isella, Lorenzo Capussotti, Paolo M. Comoglio, Andrea Muratore, Anna Sapino, Consalvo Petti, Livio Trusolino, Silvia Marsoni, Andrea Sartore-Bianchi, Marcello Gambacorta, Dario Ribero
Publikováno v:
Cancer Discovery; Vol 1
Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from therapy with anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the identification of novel biomarkers for better personalized medicine.
Autor:
Adi F. Gazdar, Hisao Imai, Junichi Soh, John D. Minna, Luc Girard, Jill E. Larsen, Mitsuo Sato, Yang Xie, Michael Peyton, Masatomo Mori, Noriko Yanagitani, Noriaki Sunaga, David S. Shames, Kyoichi Kaira
Publikováno v:
Molecular Cancer Therapeutics. 10:336-346
Oncogenic KRAS is found in more than 25% of lung adenocarcinomas, the major histologic subtype of non–small cell lung cancer (NSCLC), and is an important target for drug development. To this end, we generated four NSCLC lines with stable knockdown
Autor:
Nan Song, Ashok Srinivasan, Angela M. Davies, Ying Wang, Peter C. Lucas, Alshad S. Lalani, Rekha Pal, Carmen J. Allegra, Katherine L. Pogue-Geile, Samuel A. Jacobs
Publikováno v:
Cancer Research. 78:LB-087
Background: KRAS MT CRC tumors demonstrate constitutively activated RAF-MEK-ERK signaling pathways and resistance to anti-EGFR therapies. In preclinical studies using KRAS MT CRC cell lines, resistance to MEK inhibitors (MEKi) led to induction of ERB